Health systems are losing 18 to 30 percent of oncology revenue to uncaptured leakage. Not to bad payers or bad luck, but to documentation that does not match clinical intent, authorizations that arrive late, and charges that never make it onto a claim.
We find it, we recover it, and we rebuild the process so it stops happening.
The Leakage Is Structural
Prior authorization has become a high-interest administrative tax on your cash flow. Ninety percent of oncology practices have added staff solely to manage the paperwork, and the 2026 coding restructure gave payers fresh grounds to re-review work that was already approved.
Most revenue cycle work in oncology audits the back end. It counts what was lost after the claim was denied, which tells you the size of the problem and nothing about the cause. The cause sits upstream, in the handoff between the clinical team and the revenue cycle team, and in most systems nobody owns it.
What We Do
Charge Capture and Documentation Integrity
Deep-dive audits across Epic, ARIA, and MOSAIQ, read by clinical intent and coded output rather than by document title.
Prior Authorization Redesign
Medical necessity documentation, authorization timing, and the handoff between clinical and revenue cycle teams, rebuilt before a denial happens.
Denial Prevention and Payer Performance
Root cause by payer, by code, by site of service, so the pattern gets fixed instead of the claim.
Total Cost of Care Modeling
What a service actually costs to deliver measured against what it actually collects.
We Work Inside the System You Have
We do not run your revenue cycle. We work inside the one you already have, alongside your existing team and your existing vendor, and we leave behind a process your staff can run without us.
That distinction matters more than it sounds. A vendor is compensated for staying. We are compensated for being unnecessary.
FAQ
Revenue leakage is earned revenue that never gets collected because of a breakdown between clinical delivery and the claim. In oncology it concentrates in a few predictable places: treatment documentation that does not support the code submitted, authorizations obtained for the wrong modality or the wrong number of fractions, charges for supplies and services that never post, and payer downgrades that go unappealed. Industry estimates place the exposure at 18 to 30 percent of oncology revenue.
An initial assessment typically runs four to six weeks, covering a documentation and coding audit across your treatment planning and EHR systems, a denial pattern analysis by payer and code, and an authorization workflow review. Implementation timelines depend on what the assessment surfaces, though the front-end fixes generally move faster than the system-level ones.
No. We work alongside whatever you have in place. Most leakage in oncology originates upstream of the vendor, in clinical documentation and authorization workflow, which means replacing the vendor rarely solves it. Where a vendor is genuinely underperforming, we will say so, but that is a finding rather than a starting assumption.
A revenue integrity assessment gives you a defensible number and the root cause behind it, not an estimate.
